SlideShare a Scribd company logo
JAUNDICE

Vineela Nekkanti
V Pharm.D
Contents of the topic
 Definition
 Classification
 Signs and symptoms
 Diagnosis

 Pathophysiology
 Prevention

 Treatment
Definition :
Jaundice, as in the French jaune, refers to the yellow
discoloration of the skin.

Also known as Icterus
Jaundice is a liver disease characterized by elevated
levels of bilirubin in the blood termed as
hyperbilirubinaemia.
Normal range of serum bilirubin concentration is 0.31.3mg/dl
Jaundice occurs when bilirubin levels exceeds 2mg/dl
 Introduction to Bilirubin :
Bilirubin is a orange-yellow pigment formed in the liver
by the breakdown of hemoglobin and excreted in bile.

 Two types of bilirubin :
Conjugated and Unconjugated bilirubin

 Sources of Bilirubin :
• Catabolism of heme of hemoglobin (80-85%)
• Non-hemoglobin heme containing pigments such as
myoglobin, catalase and cytochromes
Conjugated Bilirubin

Unconjugated Bilirubin

Water soluble

Water Insoluble

It reacts quickly to produce
azobilirubin

It reacts slowly to produce
azobilirubin

It produces azobilirubin only in
the presence of dye

It produces azobilirubin in the
absence of dye

Known by Direct bilirubin

Known by Indirect bilirubin
Metabolism of Bilirubin
Types of Jaundice
 Prehepatic Jaundice
 Intrahepatic jaundice
 Post hepatic Jaundice
Type of Jaundice

Pre-Hepatic

Intra-hepatic

Post-Hepatic

Other Name

Hemolytic
jaundice

Hepatocellular
Jaundice

Obstructive/
Regurgitation
Jaundice

Cause

Increased
hemolysis of
erythrocytes

Examples

Malaria, sickle cell
anemia,
incompatible
blood transfusion

Dysfunction of liver Obstruction of bile
due to damage to duct – prevents the
parenchymal cells passage of bile into
intestine
Viral
infection(hepatitis),
poisons and
toxins(chloroform,
carbon
tetrachloride,
phosphorus),
cirrhosis

Gallstones, cancer
of pancreas, gall
bladder and bile
duct
Type of
Jaundice

Pre-Hepatic

Intra-hepatic

Post-Hepatic

Biochemical
characteristics

serum
unconjugated
bilirubin

serum
conjugated and
unconjugated
bilirubin, SGPT
and SGOT

Serum
conjugated
bilirubin and ALP

Clinical
manifestations

Dark brown color
stools

Nausea and
anorexia

Nausea; GI pain
and clay colored
feces

Absent

Absent

Increased

Increased

Stercobilinogen Increased
content
Urobilinogen
content

Increased
Etiology/Causes
Common Drugs Associated With
Hyperbilirubinemia
HEPATOCELLULAR CAUSES
•
•
•
•
•
•
•
•
•
•
•

Acetominophen
Alcohol
Amiodarone
Azulfidine
Carbenicillin
Clindamycin
Colchicine
Cyclophosphamide
Diltiazem
Ketoconazole
Methyldopa

•
•
•
•
•
•
•
•
•
•

Niacin
Nifedipine
NSAIDs
Propylthiouracil
Pyridium
Pyrazinamide
Quinidine
Rifampicin
Salicylates
Verapamil
Common Drugs Associated With
Hyperbilirubinemia
CHOLESTATIC CAUSES





















Amitriptyline
Androgenic steroids (B)
Atenolol
Augmentin
Azathioprine
Bactrim (D)
Benzodiazeprines
Captopril
Carbamazole
Chlordiazepoxide (D))
Clofibrate
Coumadin
Cyclosporine
Danazol (B)
Dapsone
Disopyramide
Erythromycin
Estrogens (B)
Ethambutol
Floxuridine






















5-Flucytosine
Fluoroquinolones
Griseofulvin
Haloperidol (D)
Labetolol
Nicotinic acid
NSAIDs
Penicillins
Phenobarbital
Phenothiazines (D)
Phenytoin
Tamoxifen
Tegretol
Thiabendazole (D)
Thiazides
Thiouracil
Tolbutamide (D)
Tricyclics (D)
Verapamil
Zidovudine
Etiopathogenesis
1.
2.
3.
4.

5.

Increased bilirubin
production
Reduced bilirubin uptake
by hepatic cells
Disrupted intracellular
conjugation
Disrupted secretion of
bilirubin into bile
canaliculi
Intra/extra-hepatic bile
duct obstruction

Lead to increases in
free (unconj.) bilirubin

Result in rise in conj.
bilirubin levels
1. INCREASED BILIRUBIN PRODUCTION
(unconj. Hyperbilirubinemia)


Hemolysis


Increased destruction of RBCs
eg sickle cell anemia, thalassemia





Drastic increase in the amount of bilirubin produced
Unconj. bilirubin levels rise due to liver’s inability to catch up to the
increased rate of RBC destruction
Prolonged hemolysis may lead to precipitation of bilirubin salts in the
gall bladder and biliary network - result in formation of gallstones and
conditions such as cholecystitis and biliary obstruction



Other



Degradation of Hb originating from areas of tissue infarctions and
hematomas
Ineffective erythropoiesis
2. DECREASED HEPATIC UPTAKE
(unconj. Hyperbilirubinemia)
 Several drugs have been reported to inhibit
bilirubin uptake by the liver
e.g. novobiocin, flavopiridol
Hepatic cell

Plasma
Alb

Bile

B
B + GST

Alb

B :GST

B + UDPGA

CB
UGT1A1

sER

MRP2
3) DISRUPTED INTRACELLULAR
CONJUGATION
(unconj. Hyperbilirubinemia)

Neonatal jaundice
occurs in 50% of newborns
fetal bilirubin is eliminated by mother’s liver
causes:
hepatic mechanisms are not fully developed resulting in
decreased ability to conjugate bilirubin
rate of bilirubin production is increased due to shorter
lifespan of RBCs

Acquired disorders
hepatitis, cirrhosis
impaired liver function
Crigler-Najjar Syndrome, Type I (CN-I)

recessive allele; mutation-induced loss of
conjugating ability in the critical enzyme
glucuronosyltransferase
CN-II greatly reduced but detectable
glucuronosyltransferase activity due to mutation
(predominantly recessive); enzymatic activity can be
induced by drugs
 Gilbert’s Syndrome
glucuronosyl transferase activity reduced to 1030% of normal; also accompanied by defective
bilirubin uptake mechanism
4) DISRUPTED SECRETION OF BILIRUBIN INTO BILE
CANALICULI
(conj. Hyperbilirubinemia)


Dubin–Johnson Syndrome


mild conj. hyperbilirubinemia, but can increase with concurrent illness,
pregnancy, and use of oral contraceptives; otherwise asymptomatic






Inability of hepatocytes to secrete CB after it has formed
Due to mutation in the MRP2 gene (autosomal recessive trait)

Rotor Syndrome


Autosomal recessive condition characterized by increased total bilirubin
levels due to a rise in CB



Caused by a defect in transport of bilirubin into bile
5) Intra/extra-hepatic bile duct obstruction



Intra-hepatic
Obstruction of bile canaliculi, bile ductules or hepatic ducts

 Extra-hepatic
Obstruction of cystic duct or common bile duct
Cholecystitis

 Obstruction causes backup and reabsorption of CB which

results in increased blood levels of CB
Signs and Symptoms
 Skin and sclerae - yellow
 Stool - light colour, clay coloured
 Dark urine

 Pain in abdomen
 Itching
 Trouble with sleeping
 Fatigue
 Swelling
 Ascites
 Mental confusion
 Coma
 Bleeding
Diagnosis
 Medical history and examination

 Urine test
 Liver function and blood tests
 Imaging tests
 Liver biopsy
 Medical history and physical examination
Patient interview for
-

abdominal pain, itchy skin or weight loss
malaria or hepatitis A
change of colour in your urine and stools
history of prolonged alcohol misuse
Flu like symptoms
Medications
Occupation

Physical examination :
-

Yellowish discoloration of eye and skin
Swelling of legs, ankle and feet
Hepatomegaly
 Urine test :
- to measure levels of a substance called urobilinogen
- more than normal urobilinogen levels : Pre and Intra hepatic
jaundice
- Less than normal urobilinogen level : Post hepatic jaundice

 Liver function and blood tests :
Damage to liver releases liver enzymes like SGPT, SGOT and ALP
and proteins, this indicates
- Hepatitis

- Alcoholic liver disease
- cirrhosis
 Imaging tests
- CT Scan
- MRI Scan

- Ultrasound Scan
- Endoscopic retrograde cholangiopancreatography (ERCP)
Used to check for abnormalities inside the liver or bile duct

systems.

 Liver biopsy
Used to diagnosis Cirrhosis and liver cancer.
Jaundice treatment
The treatment given to someone with jaundice will depend on what
type they have, how serious it is and what caused it.
It may include tackling an underlying condition such as malaria
and bothersome symptoms, such as itching.
For genetic conditions that don't get better, like sickle cell anaemia,
a blood transfusion may be given to replenish red blood cells in the
body.
If the bile duct system is blocked, an operation may be needed to
unblock it. During these procedures measures may be taken to
help prevent further problems, such as removal of the gallbladder.
If the liver is found to be seriously damaged, a transplant may be
an option
Treatment & Therapeutic Considerations
PHOTOTHERAPY
 Through absorption of the wavelengths at the blue end of the spectrum

(blue, green and white light), bilirubin is converted into water-soluble
photoisomers. This transformation enhances the molecule’s excretion
into bile without conjugation.
PHENOBARBITAL
 This drug is not approved by FDA for use in neither adult nor
pediatric hyperbilirubinemia patients, due to possibility of significant
systemic side-effects.
 Exact pathway is not known, but it is believed to act as an inducing
agent on UDP-glucuronosyl transferase, thereby improving conjugation
of bilirubin and its excretion.

ALBUMIN
 A 25% infusion can be used in treating hyperbilirubinemia (esp. due to
hemolytic disease).
 It is used in conjunction with exchange transfusion to bind bilirubin,
enhancing its removal.
CLOFIBRATE (ATROMID-S)
 This drug has been shown to reduce bilirubin levels via an unknown
mechanism.
 Clofibrate is also associated with increased risk of developing
cholelithiasis, cholecystitis, as well as functional liver abnormalities,
which can worsen hyperbilirubinemia.

PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY
 Allows extraction of stones and thus removal of the source of
obstruction when present.
Prevention of Jaundice :
• Limit alcohol intake to not more than two drinks a day for
men or one drink a day for women.

• Avoid exposure to industrial chemicals.
• Do not use illegal drugs.
• Do not share needles or nasal snorting equipment.
• Vaccination : Hepatitis A and Hepatitis B
• Maintain healthy body weight.
Jaundice V PharmD by Vineela.N

More Related Content

What's hot

Drug induced hematological disorders
Drug induced hematological disordersDrug induced hematological disorders
Drug induced hematological disorders
Dr. Jibin Mathew
 
Drug induced blood disorders
Drug induced blood disordersDrug induced blood disorders
Drug induced blood disorders
AnjumAhamadi1
 
Drug utilization evaluation
Drug utilization evaluationDrug utilization evaluation
Drug utilization evaluation
Dr. Ramesh Bhandari
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
aishuanju
 
Critical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacyCritical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacy
ShaistaSumayya
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
Dr. Ramesh Bhandari
 
Pharmacotherapy of ibd
Pharmacotherapy of ibdPharmacotherapy of ibd
Alcoholic liver disease a brief insight- by Rxvichu! :)
Alcoholic liver disease  a brief insight- by Rxvichu! :)Alcoholic liver disease  a brief insight- by Rxvichu! :)
Alcoholic liver disease a brief insight- by Rxvichu! :)
RxVichuZ
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Abel C. Mathew
 
Drug induced kidney disease (injury)
Drug induced kidney disease (injury)Drug induced kidney disease (injury)
Drug induced kidney disease (injury)
Dr. Ankit Gaur
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failure
Pallavi Kurra
 
Developing therapeutic guidelines
Developing therapeutic guidelines  Developing therapeutic guidelines
Developing therapeutic guidelines
Irene Vadakkan
 
Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy
ShaistaSumayya
 
Angina ant its pharmacotherapy
Angina ant its pharmacotherapyAngina ant its pharmacotherapy
Angina ant its pharmacotherapy
Koppala RVS Chaitanya
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal disease
Areej Abu Hanieh
 
Quality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy servicesQuality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy services
varshawadnere
 
Venous thromboembolism for Pharm.D
Venous thromboembolism for Pharm.DVenous thromboembolism for Pharm.D
Venous thromboembolism for Pharm.D
Soujanya Pharm.D
 
Extracorporeal techniques
Extracorporeal techniquesExtracorporeal techniques
Extracorporeal techniques
Arjan Aryal, PharmD
 
Alcoholic Liver Disease
Alcoholic Liver DiseaseAlcoholic Liver Disease
Alcoholic Liver Disease
Flemin Thomas
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
javvadhasan
 

What's hot (20)

Drug induced hematological disorders
Drug induced hematological disordersDrug induced hematological disorders
Drug induced hematological disorders
 
Drug induced blood disorders
Drug induced blood disordersDrug induced blood disorders
Drug induced blood disorders
 
Drug utilization evaluation
Drug utilization evaluationDrug utilization evaluation
Drug utilization evaluation
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
 
Critical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacyCritical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacy
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 
Pharmacotherapy of ibd
Pharmacotherapy of ibdPharmacotherapy of ibd
Pharmacotherapy of ibd
 
Alcoholic liver disease a brief insight- by Rxvichu! :)
Alcoholic liver disease  a brief insight- by Rxvichu! :)Alcoholic liver disease  a brief insight- by Rxvichu! :)
Alcoholic liver disease a brief insight- by Rxvichu! :)
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
Drug induced kidney disease (injury)
Drug induced kidney disease (injury)Drug induced kidney disease (injury)
Drug induced kidney disease (injury)
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failure
 
Developing therapeutic guidelines
Developing therapeutic guidelines  Developing therapeutic guidelines
Developing therapeutic guidelines
 
Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy Pharmaceutical care concepts - clinical pharmacy
Pharmaceutical care concepts - clinical pharmacy
 
Angina ant its pharmacotherapy
Angina ant its pharmacotherapyAngina ant its pharmacotherapy
Angina ant its pharmacotherapy
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal disease
 
Quality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy servicesQuality assurance of clinical pharmacy services
Quality assurance of clinical pharmacy services
 
Venous thromboembolism for Pharm.D
Venous thromboembolism for Pharm.DVenous thromboembolism for Pharm.D
Venous thromboembolism for Pharm.D
 
Extracorporeal techniques
Extracorporeal techniquesExtracorporeal techniques
Extracorporeal techniques
 
Alcoholic Liver Disease
Alcoholic Liver DiseaseAlcoholic Liver Disease
Alcoholic Liver Disease
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
 

Similar to Jaundice V PharmD by Vineela.N

JAUNDICE
JAUNDICEJAUNDICE
JAUNDICE
YESANNA
 
HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE
YESANNA
 
Liver function tests 2020
Liver function tests 2020Liver function tests 2020
Liver function tests 2020
subramaniam sethupathy
 
Liver function tests and interpretation
Liver function tests and interpretation Liver function tests and interpretation
Liver function tests and interpretation
subramaniam sethupathy
 
Heme Catabolism.ppt
Heme Catabolism.pptHeme Catabolism.ppt
Heme Catabolism.ppt
SukhenduChowdhury
 
Postoperative jaundice
Postoperative jaundicePostoperative jaundice
Postoperative jaundice
caruusha media
 
All about Jaundice
All about JaundiceAll about Jaundice
All about Jaundiceozhin araz
 
Jaundice pathology
Jaundice pathologyJaundice pathology
Jaundice pathology
MBBS Lecture Academy
 
Red Blood Cell Destruction kau
Red Blood Cell Destruction kauRed Blood Cell Destruction kau
Red Blood Cell Destruction kauguestbce519
 
Jaundice.pptx
Jaundice.pptxJaundice.pptx
Jaundice.pptx
NishathZaib
 
jaundice.pptx
jaundice.pptxjaundice.pptx
jaundice.pptx
Shubham Shukla
 
jaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdfjaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdf
IbrahimKargbo13
 
Jaundice (new).ppt
Jaundice (new).pptJaundice (new).ppt
Jaundice (new).ppt
AshidhasMEROONBELLS
 
Jaundice
JaundiceJaundice
Jaundice
ERIC GENERAL
 
Jaundice
JaundiceJaundice
LIVER FUNCTION TEST
LIVER FUNCTION TESTLIVER FUNCTION TEST
LIVER FUNCTION TEST
Yaalok
 
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptxBilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
mohamedkallon1996
 
jaundice 22.pptx
jaundice 22.pptxjaundice 22.pptx
jaundice 22.pptx
SahilVerma19852
 

Similar to Jaundice V PharmD by Vineela.N (20)

JAUNDICE
JAUNDICEJAUNDICE
JAUNDICE
 
HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE
 
Liver function tests 2020
Liver function tests 2020Liver function tests 2020
Liver function tests 2020
 
Liver function tests and interpretation
Liver function tests and interpretation Liver function tests and interpretation
Liver function tests and interpretation
 
Heme Catabolism.ppt
Heme Catabolism.pptHeme Catabolism.ppt
Heme Catabolism.ppt
 
Postoperative jaundice
Postoperative jaundicePostoperative jaundice
Postoperative jaundice
 
All about Jaundice
All about JaundiceAll about Jaundice
All about Jaundice
 
LIVER FUNCTIONS TESTS -1-
LIVER FUNCTIONS TESTS -1-LIVER FUNCTIONS TESTS -1-
LIVER FUNCTIONS TESTS -1-
 
Jaundice pathology
Jaundice pathologyJaundice pathology
Jaundice pathology
 
Red Blood Cell Destruction kau
Red Blood Cell Destruction kauRed Blood Cell Destruction kau
Red Blood Cell Destruction kau
 
Jaundice.pptx
Jaundice.pptxJaundice.pptx
Jaundice.pptx
 
jaundice.pptx
jaundice.pptxjaundice.pptx
jaundice.pptx
 
jaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdfjaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdf
 
Jaundice (new).ppt
Jaundice (new).pptJaundice (new).ppt
Jaundice (new).ppt
 
Jaundice
JaundiceJaundice
Jaundice
 
Bilirubin ...dotx
Bilirubin ...dotxBilirubin ...dotx
Bilirubin ...dotx
 
Jaundice
JaundiceJaundice
Jaundice
 
LIVER FUNCTION TEST
LIVER FUNCTION TESTLIVER FUNCTION TEST
LIVER FUNCTION TEST
 
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptxBilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
 
jaundice 22.pptx
jaundice 22.pptxjaundice 22.pptx
jaundice 22.pptx
 

More from Dr.Sohel Memon

Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDDr.Sohel Memon
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.DDr.Sohel Memon
 
Psoriasis and scabies by manaswi
Psoriasis and scabies by manaswiPsoriasis and scabies by manaswi
Psoriasis and scabies by manaswiDr.Sohel Memon
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonDr.Sohel Memon
 

More from Dr.Sohel Memon (6)

Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
 
COPD by Vineela N.
COPD by Vineela N.COPD by Vineela N.
COPD by Vineela N.
 
Psoriasis and scabies by manaswi
Psoriasis and scabies by manaswiPsoriasis and scabies by manaswi
Psoriasis and scabies by manaswi
 
Eczema by Manaswi
Eczema by ManaswiEczema by Manaswi
Eczema by Manaswi
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel Memon
 

Recently uploaded

TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
Jheel Barad
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
Anna Sz.
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
RaedMohamed3
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
GeoBlogs
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Thiyagu K
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
Tamralipta Mahavidyalaya
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
Pavel ( NSTU)
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 

Recently uploaded (20)

TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Polish students' mobility in the Czech Republic
Polish students' mobility in the Czech RepublicPolish students' mobility in the Czech Republic
Polish students' mobility in the Czech Republic
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 
Palestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptxPalestine last event orientationfvgnh .pptx
Palestine last event orientationfvgnh .pptx
 
The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
Unit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdfUnit 2- Research Aptitude (UGC NET Paper I).pdf
Unit 2- Research Aptitude (UGC NET Paper I).pdf
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 

Jaundice V PharmD by Vineela.N

  • 2. Contents of the topic  Definition  Classification  Signs and symptoms  Diagnosis  Pathophysiology  Prevention  Treatment
  • 3. Definition : Jaundice, as in the French jaune, refers to the yellow discoloration of the skin. Also known as Icterus Jaundice is a liver disease characterized by elevated levels of bilirubin in the blood termed as hyperbilirubinaemia. Normal range of serum bilirubin concentration is 0.31.3mg/dl Jaundice occurs when bilirubin levels exceeds 2mg/dl
  • 4.  Introduction to Bilirubin : Bilirubin is a orange-yellow pigment formed in the liver by the breakdown of hemoglobin and excreted in bile.  Two types of bilirubin : Conjugated and Unconjugated bilirubin  Sources of Bilirubin : • Catabolism of heme of hemoglobin (80-85%) • Non-hemoglobin heme containing pigments such as myoglobin, catalase and cytochromes
  • 5. Conjugated Bilirubin Unconjugated Bilirubin Water soluble Water Insoluble It reacts quickly to produce azobilirubin It reacts slowly to produce azobilirubin It produces azobilirubin only in the presence of dye It produces azobilirubin in the absence of dye Known by Direct bilirubin Known by Indirect bilirubin
  • 7.
  • 8. Types of Jaundice  Prehepatic Jaundice  Intrahepatic jaundice  Post hepatic Jaundice
  • 9.
  • 10. Type of Jaundice Pre-Hepatic Intra-hepatic Post-Hepatic Other Name Hemolytic jaundice Hepatocellular Jaundice Obstructive/ Regurgitation Jaundice Cause Increased hemolysis of erythrocytes Examples Malaria, sickle cell anemia, incompatible blood transfusion Dysfunction of liver Obstruction of bile due to damage to duct – prevents the parenchymal cells passage of bile into intestine Viral infection(hepatitis), poisons and toxins(chloroform, carbon tetrachloride, phosphorus), cirrhosis Gallstones, cancer of pancreas, gall bladder and bile duct
  • 11. Type of Jaundice Pre-Hepatic Intra-hepatic Post-Hepatic Biochemical characteristics serum unconjugated bilirubin serum conjugated and unconjugated bilirubin, SGPT and SGOT Serum conjugated bilirubin and ALP Clinical manifestations Dark brown color stools Nausea and anorexia Nausea; GI pain and clay colored feces Absent Absent Increased Increased Stercobilinogen Increased content Urobilinogen content Increased
  • 12.
  • 14. Common Drugs Associated With Hyperbilirubinemia HEPATOCELLULAR CAUSES • • • • • • • • • • • Acetominophen Alcohol Amiodarone Azulfidine Carbenicillin Clindamycin Colchicine Cyclophosphamide Diltiazem Ketoconazole Methyldopa • • • • • • • • • • Niacin Nifedipine NSAIDs Propylthiouracil Pyridium Pyrazinamide Quinidine Rifampicin Salicylates Verapamil
  • 15. Common Drugs Associated With Hyperbilirubinemia CHOLESTATIC CAUSES                     Amitriptyline Androgenic steroids (B) Atenolol Augmentin Azathioprine Bactrim (D) Benzodiazeprines Captopril Carbamazole Chlordiazepoxide (D)) Clofibrate Coumadin Cyclosporine Danazol (B) Dapsone Disopyramide Erythromycin Estrogens (B) Ethambutol Floxuridine                     5-Flucytosine Fluoroquinolones Griseofulvin Haloperidol (D) Labetolol Nicotinic acid NSAIDs Penicillins Phenobarbital Phenothiazines (D) Phenytoin Tamoxifen Tegretol Thiabendazole (D) Thiazides Thiouracil Tolbutamide (D) Tricyclics (D) Verapamil Zidovudine
  • 16. Etiopathogenesis 1. 2. 3. 4. 5. Increased bilirubin production Reduced bilirubin uptake by hepatic cells Disrupted intracellular conjugation Disrupted secretion of bilirubin into bile canaliculi Intra/extra-hepatic bile duct obstruction Lead to increases in free (unconj.) bilirubin Result in rise in conj. bilirubin levels
  • 17. 1. INCREASED BILIRUBIN PRODUCTION (unconj. Hyperbilirubinemia)  Hemolysis  Increased destruction of RBCs eg sickle cell anemia, thalassemia    Drastic increase in the amount of bilirubin produced Unconj. bilirubin levels rise due to liver’s inability to catch up to the increased rate of RBC destruction Prolonged hemolysis may lead to precipitation of bilirubin salts in the gall bladder and biliary network - result in formation of gallstones and conditions such as cholecystitis and biliary obstruction  Other   Degradation of Hb originating from areas of tissue infarctions and hematomas Ineffective erythropoiesis
  • 18. 2. DECREASED HEPATIC UPTAKE (unconj. Hyperbilirubinemia)  Several drugs have been reported to inhibit bilirubin uptake by the liver e.g. novobiocin, flavopiridol Hepatic cell Plasma Alb Bile B B + GST Alb B :GST B + UDPGA CB UGT1A1 sER MRP2
  • 19. 3) DISRUPTED INTRACELLULAR CONJUGATION (unconj. Hyperbilirubinemia) Neonatal jaundice occurs in 50% of newborns fetal bilirubin is eliminated by mother’s liver causes: hepatic mechanisms are not fully developed resulting in decreased ability to conjugate bilirubin rate of bilirubin production is increased due to shorter lifespan of RBCs Acquired disorders hepatitis, cirrhosis impaired liver function
  • 20.
  • 21. Crigler-Najjar Syndrome, Type I (CN-I) recessive allele; mutation-induced loss of conjugating ability in the critical enzyme glucuronosyltransferase CN-II greatly reduced but detectable glucuronosyltransferase activity due to mutation (predominantly recessive); enzymatic activity can be induced by drugs  Gilbert’s Syndrome glucuronosyl transferase activity reduced to 1030% of normal; also accompanied by defective bilirubin uptake mechanism
  • 22. 4) DISRUPTED SECRETION OF BILIRUBIN INTO BILE CANALICULI (conj. Hyperbilirubinemia)  Dubin–Johnson Syndrome  mild conj. hyperbilirubinemia, but can increase with concurrent illness, pregnancy, and use of oral contraceptives; otherwise asymptomatic    Inability of hepatocytes to secrete CB after it has formed Due to mutation in the MRP2 gene (autosomal recessive trait) Rotor Syndrome  Autosomal recessive condition characterized by increased total bilirubin levels due to a rise in CB  Caused by a defect in transport of bilirubin into bile
  • 23.
  • 24. 5) Intra/extra-hepatic bile duct obstruction  Intra-hepatic Obstruction of bile canaliculi, bile ductules or hepatic ducts  Extra-hepatic Obstruction of cystic duct or common bile duct Cholecystitis  Obstruction causes backup and reabsorption of CB which results in increased blood levels of CB
  • 25. Signs and Symptoms  Skin and sclerae - yellow  Stool - light colour, clay coloured  Dark urine  Pain in abdomen  Itching  Trouble with sleeping  Fatigue  Swelling  Ascites  Mental confusion  Coma  Bleeding
  • 26. Diagnosis  Medical history and examination  Urine test  Liver function and blood tests  Imaging tests  Liver biopsy
  • 27.  Medical history and physical examination Patient interview for - abdominal pain, itchy skin or weight loss malaria or hepatitis A change of colour in your urine and stools history of prolonged alcohol misuse Flu like symptoms Medications Occupation Physical examination : - Yellowish discoloration of eye and skin Swelling of legs, ankle and feet Hepatomegaly
  • 28.  Urine test : - to measure levels of a substance called urobilinogen - more than normal urobilinogen levels : Pre and Intra hepatic jaundice - Less than normal urobilinogen level : Post hepatic jaundice  Liver function and blood tests : Damage to liver releases liver enzymes like SGPT, SGOT and ALP and proteins, this indicates - Hepatitis - Alcoholic liver disease - cirrhosis
  • 29.  Imaging tests - CT Scan - MRI Scan - Ultrasound Scan - Endoscopic retrograde cholangiopancreatography (ERCP) Used to check for abnormalities inside the liver or bile duct systems.  Liver biopsy Used to diagnosis Cirrhosis and liver cancer.
  • 30.
  • 31. Jaundice treatment The treatment given to someone with jaundice will depend on what type they have, how serious it is and what caused it. It may include tackling an underlying condition such as malaria and bothersome symptoms, such as itching. For genetic conditions that don't get better, like sickle cell anaemia, a blood transfusion may be given to replenish red blood cells in the body. If the bile duct system is blocked, an operation may be needed to unblock it. During these procedures measures may be taken to help prevent further problems, such as removal of the gallbladder. If the liver is found to be seriously damaged, a transplant may be an option
  • 32. Treatment & Therapeutic Considerations PHOTOTHERAPY  Through absorption of the wavelengths at the blue end of the spectrum (blue, green and white light), bilirubin is converted into water-soluble photoisomers. This transformation enhances the molecule’s excretion into bile without conjugation.
  • 33. PHENOBARBITAL  This drug is not approved by FDA for use in neither adult nor pediatric hyperbilirubinemia patients, due to possibility of significant systemic side-effects.  Exact pathway is not known, but it is believed to act as an inducing agent on UDP-glucuronosyl transferase, thereby improving conjugation of bilirubin and its excretion. ALBUMIN  A 25% infusion can be used in treating hyperbilirubinemia (esp. due to hemolytic disease).  It is used in conjunction with exchange transfusion to bind bilirubin, enhancing its removal.
  • 34. CLOFIBRATE (ATROMID-S)  This drug has been shown to reduce bilirubin levels via an unknown mechanism.  Clofibrate is also associated with increased risk of developing cholelithiasis, cholecystitis, as well as functional liver abnormalities, which can worsen hyperbilirubinemia. PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY  Allows extraction of stones and thus removal of the source of obstruction when present.
  • 35. Prevention of Jaundice : • Limit alcohol intake to not more than two drinks a day for men or one drink a day for women. • Avoid exposure to industrial chemicals. • Do not use illegal drugs. • Do not share needles or nasal snorting equipment. • Vaccination : Hepatitis A and Hepatitis B • Maintain healthy body weight.